Bayer

Bayer and Iambic announced a drug-discovery collaboration in which Bayer will use Iambic's AI-driven platform. The collaboration is focused on small-molecule discovery.

Partners: Iambic

Bayer announced a three-year collaboration and said it will integrate Cradle's generative AI platform into existing R&D workflows for antibody lead generation and optimization. Bayer says it selected Cradle after a successful proof of concept.

Partners: Cradle

Bayer and Aignostics announced a multi-year collaboration to identify novel cancer targets with AI models on multimodal patient data, and to develop AI and machine-learning pathology algorithms that connect pathology and clinical data for trial patient identification, stratification and selection.

Partners: Aignostics

Bayer and Recursion focused their research collaboration on precision oncology, using Recursion's AI-guided drug discovery platform. They may initiate up to seven oncology programs, and Recursion is eligible for up to $1.5 billion plus royalties on net sales.

Partners: Recursion

Bayer's AI Innovation Platform is a cloud platform, built on Google Cloud, for developing imaging AI and machine-learning healthcare applications. Bayer says it is in external testing.

Partners: Google Cloud

Bayer says Calantic Digital Solutions offers AI-enabled applications that are already available and cleared, orchestrated on one platform for everyday clinical tasks.

Bayer completed the acquisition of Blackford Analysis, which it calls a global imaging AI platform and solutions provider. The release says Blackford is now a wholly owned subsidiary and continues to operate.

Partners: Blackford Analysis

Bayer and Google Cloud announced a collaboration that applies Google Cloud TPUs, described as accelerators designed to run machine-learning models and computationally intensive workloads, to accelerate and scale Bayer's quantum chemistry calculations.

Partners: Google Cloud